The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 16, 2014
Filed:
Jan. 04, 2013
Applicant:
Merck Patent Gmbh, , unknown;
Inventors:
Gerard Botton, Buc, FR;
Eric Valeur, Bretigny sur Orge, FR;
Micheline Kergoat, Bures-sur-Yvette, FR;
Christine Charon, Gometz-le-Chatel, FR;
Samer Elbawab, Bures sur Yvette, FR;
Assignee:
Merck Patent GmbH, Darmstadt, DE;
Primary Examiner:
Int. Cl.
CPC ...
C07D 241/44 (2006.01); C07D 405/10 (2006.01); C07D 405/04 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 403/10 (2006.01); C07D 413/10 (2006.01);
U.S. Cl.
CPC ...
C07D 413/10 (2013.01); C07D 405/10 (2013.01); C07D 241/44 (2013.01); C07D 405/04 (2013.01); C07D 401/04 (2013.01); C07D 403/04 (2013.01); C07D 403/10 (2013.01);
Abstract
The present invention relates to methods for the treatment of a pathology associated with hyperglycaemia, particularly diabetes, by administering quinoxalinone compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as defined in the claims. The compounds have activity as insulin secretion stimulators. The invention also relates to the preparation and use of these quinoxalinone compounds for modulating insulin secretion in insulin-1 cells by contacting the cells with the compounds.